Latest Breaking News On - Axel bolte - Page 3 : comparemela.com

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose coh.

United statesInozyme pharmaAxel bolteYves sabbaghStefan rileyMatt peraJoseph schlessingerDemetrios braddockExchange commissionYale universityInozyme pharma incInvestor relationsCorporate presentationPrivate securities litigation reform actAnnual reportSina com hk

Inozyme Pharma Inc (INZY) Reports Positive Prelim Data from Phase 1/2 Clinical Trial of INZ-701

Inozyme Pharma Inc (INZY) Reports Positive Prelim Data from Phase 1/2 Clinical Trial of INZ-701
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesInozyme pharmastefan rileySmithsolve matt peraInozyme pharmaAxel bolteYves sabbaghJoseph schlessingerDemetrios braddockExchange commissionYale universityInozyme pharma incInvestor relationsCorporate presentationPrivate securities litigation reform actAnnual report

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United statesAxel bolteInozyme pharma inc

Inozyme Pharma (NASDAQ:INZY) Raised to Buy at Zacks Investment Research

Inozyme Pharma (NASDAQ:INZY – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday, Zacks.com reports. The brokerage presently has a $4.50 target price on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 8.17% from the company’s current […]

New yorkUnited statesInozyme pharmaAxel bolteHenric bjorn bjarkeMorgan stanleyNorthern trust corpYork state common retirement fundSecurities exchange commissionInozyme pharma incZacks investment researchNeedham companyMarshall waceYork mellon corpGet ratingInvestment research

Inozyme Pharma (NASDAQ:INZY) Stock Rating Reaffirmed by Wedbush

Inozyme Pharma (NASDAQ:INZY – Get Rating)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research report issued to clients and investors on Tuesday, RTT News reports. They presently have a $23.00 target price on the stock, down from their prior target price of $25.00. Wedbush’s price objective would indicate a […]

New yorkUnited statesInozyme pharmaAxel bolteRobert lorne hopfnerMorgan stanleyYork state common retirement fundGeode capital managementRussell investments group ltdInozyme pharma incZacks investment researchNeedham companySg americas securitiesGet ratingDirector robert lorne hopfnerInvestments group